Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iradimed (IRMD) EBT (2016 - 2026)

Iradimed has reported EBT over the past 14 years, most recently at $7.8 million for Q1 2026.

  • Quarterly EBT rose 30.68% to $7.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $30.2 million through Mar 2026, up 20.85% year-over-year, with the annual reading at $28.4 million for FY2025, 16.83% up from the prior year.
  • EBT was $7.8 million for Q1 2026 at Iradimed, roughly flat from $7.8 million in the prior quarter.
  • Over five years, EBT peaked at $7.8 million in Q4 2025 and troughed at $3.1 million in Q1 2022.
  • The 5-year median for EBT is $5.9 million (2025), against an average of $5.8 million.
  • Year-over-year, EBT surged 125.03% in 2022 and then grew 0.15% in 2024.
  • A 5-year view of EBT shows it stood at $4.7 million in 2022, then grew by 20.79% to $5.7 million in 2023, then increased by 11.66% to $6.3 million in 2024, then rose by 22.8% to $7.8 million in 2025, then decreased by 0.28% to $7.8 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's EBT are $7.8 million (Q1 2026), $7.8 million (Q4 2025), and $7.3 million (Q3 2025).